have already occurred. And while having more options strengthens overall MS care, the missing puzzle piece has been determining how and when to best deploy those treatments to people living with the disease and their symptom realities at any given moment along their ever-evolving journey.
Linked by a shared, long-term commitment to solve that puzzle, Novartis Pharmaceuticals Canada Inc. and Innodem Neurosciences, joined forces with the aim to accelerate the path to solutions.Together, we are studying how eye movement biomarkers and gaze mapping biomarkers may support clinicians in analyzing highly sensitive data to monitor and detect subtle changes in disease progression.
Our partnership has opened doors to solutions and resources that may not have been within reach if we were to operate individually. From the beginning, we have been able to bring key stakeholders to the brainstorming table. These important discussions among top experts support integration and ensure we don’t become siloed or build solutions based on internal assumptions and biases.
We strongly believe in, and continue to witness firsthand, the power collaboration and knowledge-sharing can have on meaningful and lasting change. We are confident and optimistic that the ability to tap into a national ecosystem of talent will continue to lead to advancements that redefine how we provide care and our understanding of what ideal patient outcomes look like — now, and in the future.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: globeandmail - 🏆 5. / 92 Lire la suite »
La source: GlobalNational - 🏆 81. / 51 Lire la suite »